Management tracks: Sihuan launches U.S. unit

Sihuan Pharmaceutical Holdings Group Ltd. (HKSE:460) established a global business development unit in the U.S., through which it is seeking to expand and speed its international projects. The unit will be led by CBO Frank Leslie Boyd Jr., Global Head of Oncology Business Development Joyce Pei, Global Head of Transactions Business Development J. Michael French and Global Head of Competitive Intelligence Guoqiang Jiang.

Before joining the company, Boyd was VP of search and evaluation for specialty R&D at Teva Pharmaceutical Industries Ltd. (Tel Aviv:TEVA; NYSE:TEVA). Pei was U.S. head of business development and investment at Simcere Pharmaceutical Group (Nanjing, China). French was chairman, president and CEO of Marina Biotech Inc. (Pink:MRNAD). Jiang was director of strategic product and pipeline intelligence at Merck & Co. Inc. (NYSE:MRK)...